View ValuationEmbecta 将来の成長Future 基準チェック /06Embectaの収益は年間1.9%で減少すると予測されていますが、年間収益は年間1.7%で増加すると予想されています。EPS は年間0.8%で増加すると予想されています。主要情報-1.9%収益成長率0.84%EPS成長率Medical Equipment 収益成長13.5%収益成長率1.7%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日18 May 2026今後の成長に関する最新情報お知らせ • Nov 25+ 1 more updateEmbecta Corp. Provides Earnings Guidance for the Fiscal Year 2026Embecta Corp. provided earnings guidance for the fiscal year 2026. For the year, the company expects reported revenues of $1,071 million to $1,093 million.お知らせ • May 22Embecta Corp. Re-Affirms Earnings Guidance for the Fiscal Year 2025Embecta Corp. re-affirmed earnings guidance for the fiscal year 2025. For the year, the company expected Reported Revenues of $1,073 million - $1,090 million.お知らせ • Feb 06+ 1 more updateEmbecta Corp. Revises Earnings Guidance for the Fiscal Year 2025Embecta Corp. revised earnings guidance for the Fiscal Year 2025 . For the year, company expected Reported Revenues to be in range of $1,075 million to $1,092 million compared to $1,093 million to $1,110 million.お知らせ • Nov 26+ 1 more updateEmbecta Corp. Provides Earnings Guidance for the Fiscal Year 2025Embecta Corp. provided earnings guidance for the Fiscal Year 2025 . For the year, company expected Reported Revenues to be in range of $1,093 million to $1,110 million.お知らせ • Aug 09+ 1 more updateEmbecta Corp. Revises Earnings Guidance for the Fiscal Year 2024Embecta Corp. revised earnings guidance for the fiscal year 2024. For the fiscal year, the Company now expects revenues of $1,111 million to $1,116 million same as previous guidance of $1,111 million to $1,116 million.お知らせ • May 10+ 1 more updateEmbecta Corp. Provides Earnings Guidance for the Fiscal Year 2024Embecta Corp. provided earnings guidance for the fiscal year 2024. For the year, the company expects revenues to be $1,111 million -$1,116 million against previous guidance of $1,094 million- $1,116 million.すべての更新を表示Recent updatesBoard Change • May 21Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Lead Independent Director Claire Pomeroy was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • May 06Embecta Corp. (NasdaqGS:EMBC) announces an Equity Buyback for $100 million worth of its shares.Embecta Corp. (NasdaqGS:EMBC) announces a share repurchase program. Under the program, the company will repurchase up to $100 million worth of its stock. The program is valid for 3 years.お知らせ • Feb 12Embecta Announces Board Changes, Effective February 11, 2026Embecta announced that its board of directors elected the company’s CEO, Devdatt “Dev” Kurdikar, as chair. The Parsippany, New Jersey-based BD Diabetes spinoff also named Dr. Claire Pomeroy as lead independent director. Both appointments go into effect immediately. These changes follow the retirement of David Melcher, who previously served as non-executive chair of the board. Kurdikar,57, joined BD in 2021 to join the company’s diabetes care business, overseeing it during its separation from the medtech giant. He assumed the role of president and CEO of Embecta following the 2022 spin-off, also joining the company’s board. Changes come atop the company’s board as Embecta works through brand transition program through a phased plan to create value and shift priorities toward broader medical applications. Pomeroy,70, joined Embecta’s board of directors at its inception in 2022. In addition to serving as lead independent director, she will continue to chair the board’s Corporate Governance and Nominating Committee and serve on the Technology, Quality and Regulatory Committee. Other roles for Pomeroy include president of the Albert and Mary Lasker Foundation, a private foundation. It seeks to improve health by accelerating support for medical research through research excellence, public education and advocacy. Pomeroy also serves as a director of Haemonetics and on a number of other boards across several foundations, centers, labs, schools and more.お知らせ • Feb 06Embecta Corp. Announces Quarterly Cash Dividend, Payable on March 17, 2026Embecta Corp. has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company’s common stock. The dividend is payable on March 17, 2026 to stockholders of record at the close of business on February 27, 2026.お知らせ • Dec 19Embecta Corp., Annual General Meeting, Feb 11, 2026Embecta Corp., Annual General Meeting, Feb 11, 2026.お知らせ • Nov 25+ 1 more updateEmbecta Corp. Provides Earnings Guidance for the Fiscal Year 2026Embecta Corp. provided earnings guidance for the fiscal year 2026. For the year, the company expects reported revenues of $1,071 million to $1,093 million.お知らせ • Nov 18Embecta Corp. Announces Board ChangesEmbecta Corp. announced that on November 17, 2025, David A. Albritton, a member of the board of directors of the company, the Corporate Governance and Nominating Committee of the Board and the Technology, Quality and Regulatory Committee of the Board, notified the Company of his intention to resign due to personal reasons, effective immediately. Mr. Albritton has served as a director of the Company since April 2022. Mr. Albritton’s resignation was not the result of any disagreement with the Company or any matter relating to its operations, policies or practices. On November 17, 2025, LTG (Ret.) David F. Melcher, a member of the Board and the Non-Executive Chairman of the Board, notified the Company of his decision not to stand for re-election at the Company’s 2026 annual meeting of stockholders. LTG Melcher has served as a director of the Company since April 2022. LTG Melcher’s decision not to stand for reelection was not the result of any disagreement with the Company or any matter relating to its operations, policies or practices. In connection with the resignation of Mr. Albritton, the size of the Board was decreased from nine to eight members. The Company’s independent directors expect to appoint Devdatt (Dev) Kurdikar as the Chairman of the Board and Dr. Claire Pomeroy as the Board’s Lead Independent Director, each effective upon LTG Melcher’s departure from the Board at the Company’s 2026 annual meeting of stockholders. Dr. Pomeroy and Mr. Kurdikar have served on the Board since April 2022. Dr. Pomeroy currently serves as Chair of the Corporate Governance and Nominating Committee and as a member of the Technology, Quality and Regulatory Committee, and Mr. Kurdikar currently serves as the President and Chief Executive Officer of the Company.お知らせ • Nov 12Embecta Corp. to Report Q4, 2025 Results on Nov 25, 2025Embecta Corp. announced that they will report Q4, 2025 results on Nov 25, 2025お知らせ • Aug 08Embecta Corp. Declares Quarterly Cash Dividend, Payable on September 15, 2025The Board of Directors of Embecta Corp. has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company’s common stock. The dividend is payable on September 15, 2025 to stockholders of record at the close of business on August 29, 2025.お知らせ • May 22Embecta Corp. Re-Affirms Earnings Guidance for the Fiscal Year 2025Embecta Corp. re-affirmed earnings guidance for the fiscal year 2025. For the year, the company expected Reported Revenues of $1,073 million - $1,090 million.お知らせ • May 09+ 1 more updateEmbecta Corp. Announces Quarterly Cash Dividend, Payable on June 13, 2025The Board of Directors of Embecta Corp. has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company’s common stock. The dividend is payable on June 13, 2025 to stockholders of record at the close of business on May 28, 2025.お知らせ • Apr 22Embecta Corp. to Report Q2, 2025 Results on May 09, 2025Embecta Corp. announced that they will report Q2, 2025 results on May 09, 2025お知らせ • Feb 06+ 1 more updateEmbecta Corp. Revises Earnings Guidance for the Fiscal Year 2025Embecta Corp. revised earnings guidance for the Fiscal Year 2025 . For the year, company expected Reported Revenues to be in range of $1,075 million to $1,092 million compared to $1,093 million to $1,110 million.お知らせ • Jan 24Embecta Corp. to Report Q1, 2025 Results on Feb 06, 2025Embecta Corp. announced that they will report Q1, 2025 results on Feb 06, 2025お知らせ • Dec 20Embecta Corp., Annual General Meeting, Feb 12, 2025Embecta Corp., Annual General Meeting, Feb 12, 2025. Location: the hilton short hills, 41 john f. kennedy parkway, short hills, new jersey, United Statesお知らせ • Dec 03Embecta Corp. Announces Executive ChangesEmbecta Corp. appointed Anthony Roth as Chief Accounting Officer and Corporate Controller of the Company and principal accounting officer of the Company, effective as of December 2, 2024. Prior to joining the Company, Mr. Roth, 51, served as Senior Vice President, Chief Accounting Officer for Ascential plc’s Digital Commerce business during 2023 and as Chief Accounting Officer and Corporate Controller for Summit Health, from 2020 to 2023. Prior to his time with Summit Health, he served as Senior Vice President, Finance and Corporate Controller with Phibro Animal Health Corporation. Mr. Roth, a certified public accountant, has also held various accounting and financial reporting positions across several companies, including Squarespace Inc., ConvaTec Inc. and Travelport Limited. In connection with the appointment of Mr. Roth, Jake Elguicze stepped down as the Company’s principal accounting officer, effective December 2, 2024. Mr. Elguicze will continue to serve as the Company’s Chief Financial Officer and principal financial officer.お知らせ • Dec 01Embecta Corp. announced delayed annual 10-K filingOn 11/29/2024, Embecta Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Nov 26+ 1 more updateEmbecta Corp. Provides Earnings Guidance for the Fiscal Year 2025Embecta Corp. provided earnings guidance for the Fiscal Year 2025 . For the year, company expected Reported Revenues to be in range of $1,093 million to $1,110 million.お知らせ • Nov 13Embecta Corp. to Report Q4, 2024 Results on Nov 26, 2024Embecta Corp. announced that they will report Q4, 2024 results on Nov 26, 2024Valuation Update With 7 Day Price Move • Nov 08Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €14.90, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 23x in the Medical Equipment industry in Germany. Total returns to shareholders of 10% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €28.37 per share.お知らせ • Sep 03Embecta Corp. Receives 510(k) Clearance from the U.S. Food and Drug Administration for Disposable Insulin Delivery SystemEmbecta Corp. announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its proprietary disposable insulin delivery system. Indicated for adults who require insulin to manage diabetes, including both type 1 (T1D) and type 2 (T2D), the system includes a tubeless patch pump design with a 300-unit insulin reservoir that was informed by feedback from people with T2D and their healthcare providers. The system includes a wearable, fully disposable patch pump that provides adjustable basal and bolus insulin for up to three days, depending on the needs of the user. The patch pump features a 300-unit insulin reservoir that accommodates people who have higher daily insulin needs, which is typically true of people with T2D. For such people, the on-market patch pumps may not hold enough insulin to meet their needs for three days. For example, a recent embecta-sponsored study showed that a 300-unit insulin reservoir would meet the needs of 64% of adults with T2D for three-day wear, while a 200-unit reservoir would only meet the needs of 38% of that same population. In addition to the patch pump, the system comprises a locked-down controller featuring Bluetooth wireless technology with a color touchscreen designed to create a simplified interface and user experience. embecta’s patch pump development program also includes plans for a closed-loop version including an insulin-dosing algorithm in a future FDA submission.Valuation Update With 7 Day Price Move • Aug 30Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €13.80, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 25x in the Medical Equipment industry in Germany. Total loss to shareholders of 13% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €22.16 per share.Upcoming Dividend • Aug 21Upcoming dividend of US$0.15 per shareEligible shareholders must have bought the stock before 27 August 2024. Payment date: 13 September 2024. Payout ratio is a comfortable 50% but the company is paying out more than the cash it is generating. Trailing yield: 4.4%. Lower than top quartile of German dividend payers (4.8%). Higher than average of industry peers (1.9%).Declared Dividend • Aug 15Third quarter dividend of US$0.15 announcedShareholders will receive a dividend of US$0.15. Ex-date: 27th August 2024 Payment date: 13th September 2024 Dividend yield will be 4.3%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by earnings (50% earnings payout ratio) but not covered by cash flows (253% cash payout ratio). The dividend has not increased over the past 2 years but payments have been stable during that time. EPS is expected to grow by 61% over the next 2 years, which should provide support to the dividend and adequate earnings cover.Reported Earnings • Aug 11Third quarter 2024 earnings released: EPS: US$0.25 (vs US$0.27 in 3Q 2023)Third quarter 2024 results: EPS: US$0.25 (down from US$0.27 in 3Q 2023). Revenue: US$272.5m (down 4.8% from 3Q 2023). Net income: US$14.7m (down 3.3% from 3Q 2023). Profit margin: 5.4% (up from 5.3% in 3Q 2023). Revenue is forecast to stay flat during the next 3 years compared to a 6.5% growth forecast for the Medical Equipment industry in Germany.お知らせ • Aug 09+ 1 more updateEmbecta Corp. Revises Earnings Guidance for the Fiscal Year 2024Embecta Corp. revised earnings guidance for the fiscal year 2024. For the fiscal year, the Company now expects revenues of $1,111 million to $1,116 million same as previous guidance of $1,111 million to $1,116 million.New Risk • Jul 24New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.7x net interest cover). Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-US$770m). Minor Risks Dividend is not well covered by cash flows (368% cash payout ratio). Large one-off items impacting financial results.お知らせ • Jul 19Embecta Corp. to Report Q3, 2024 Results on Aug 09, 2024Embecta Corp. announced that they will report Q3, 2024 results on Aug 09, 2024Valuation Update With 7 Day Price Move • Jul 18Investor sentiment improves as stock rises 18%After last week's 18% share price gain to €11.90, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 26x in the Medical Equipment industry in Germany. Total loss to shareholders of 29% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €5.25 per share.Valuation Update With 7 Day Price Move • May 16Investor sentiment improves as stock rises 30%After last week's 30% share price gain to €13.30, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 27x in the Medical Equipment industry in Germany. Total loss to shareholders of 46% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €5.81 per share.Declared Dividend • May 13Second quarter dividend of US$0.15 announcedShareholders will receive a dividend of US$0.15. Ex-date: 24th May 2024 Payment date: 14th June 2024 Dividend yield will be 4.4%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by earnings (49% earnings payout ratio) but not covered by cash flows (368% cash payout ratio). The dividend has not increased over the past 2 years but payments have been stable during that time. EPS is expected to grow by 60% over the next 3 years, which should provide support to the dividend and adequate earnings cover.New Risk • May 10New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 4.9% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.5x net interest cover). Negative equity (-US$770m). Earnings are forecast to decline by an average of 4.9% per year for the foreseeable future. Minor Risks Dividend is not well covered by cash flows (368% cash payout ratio). Share price has been volatile over the past 3 months (9.0% average weekly change).お知らせ • May 10+ 1 more updateEmbecta Corp. Provides Earnings Guidance for the Fiscal Year 2024Embecta Corp. provided earnings guidance for the fiscal year 2024. For the year, the company expects revenues to be $1,111 million -$1,116 million against previous guidance of $1,094 million- $1,116 million.Reported Earnings • May 10Second quarter 2024 earnings released: EPS: US$0.50 (vs US$0.24 in 2Q 2023)Second quarter 2024 results: EPS: US$0.50 (up from US$0.24 in 2Q 2023). Revenue: US$287.2m (up 3.6% from 2Q 2023). Net income: US$28.9m (up 106% from 2Q 2023). Profit margin: 10% (up from 5.1% in 2Q 2023). The increase in margin was primarily driven by higher revenue. Revenue is forecast to stay flat during the next 3 years compared to a 7.0% growth forecast for the Medical Equipment industry in Germany.お知らせ • Apr 24Embecta Corp. to Report Q2, 2024 Results on May 09, 2024Embecta Corp. announced that they will report Q2, 2024 results on May 09, 2024Valuation Update With 7 Day Price Move • Apr 16Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to €9.50, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 23x in the Medical Equipment industry in Germany. Total loss to shareholders of 61% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €5.01 per share.Upcoming Dividend • Feb 20Upcoming dividend of US$0.15 per shareEligible shareholders must have bought the stock before 27 February 2024. Payment date: 15 March 2024. Payout ratio is a comfortable 62% but the company is not cash flow positive. Trailing yield: 4.1%. Lower than top quartile of German dividend payers (5.1%). Higher than average of industry peers (1.6%).Valuation Update With 7 Day Price Move • Feb 16Investor sentiment deteriorates as stock falls 26%After last week's 26% share price decline to €13.30, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 24x in the Medical Equipment industry in Germany. Total loss to shareholders of 53% over the past year.Declared Dividend • Feb 14First quarter dividend of US$0.15 announcedShareholders will receive a dividend of US$0.15. Ex-date: 27th February 2024 Payment date: 15th March 2024 Dividend yield will be 4.2%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by earnings (62% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years. EPS is expected to grow by 111% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Reported Earnings • Feb 11First quarter 2024 earnings released: EPS: US$0.35 (vs US$0.62 in 1Q 2023)First quarter 2024 results: EPS: US$0.35 (down from US$0.62 in 1Q 2023). Revenue: US$277.3m (flat on 1Q 2023). Net income: US$20.1m (down 43% from 1Q 2023). Profit margin: 7.2% (down from 13% in 1Q 2023). Revenue is forecast to stay flat during the next 3 years compared to a 6.5% growth forecast for the Medical Equipment industry in Germany.New Risk • Feb 10New major risk - Revenue and earnings growthEarnings have declined by 40% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.1x net interest cover). Negative equity (-US$822m). Earnings have declined by 40% per year over the past 5 years. Minor Risks Short dividend paying track record (1 year of continuous dividend payments). Profit margins are more than 30% lower than last year (6.3% net profit margin).お知らせ • Feb 09+ 1 more updateEmbecta Corp. Updates Earnings Guidance for the Fiscal Year 2024Embecta Corp. updated earnings guidance for the fiscal year 2024. For the year 2024, the company expected revenues to be $1,094 million to $1,116 million against $1,085 million to $1,105 million previous guidance.お知らせ • Jan 25Embecta Corp. to Report Q1, 2024 Results on Feb 09, 2024Embecta Corp. announced that they will report Q1, 2024 results on Feb 09, 2024お知らせ • Jan 09Embecta Corp. Announces Food and Drug Administration 510(K) Submission for Insulin Patch PumpEmbecta Corp. announced that it has submitted a 510(k) premarket filing to the U.S. Food and Drug Administration (FDA) for a proprietary disposable insulin delivery system. embecta continues to advance its patch pump development program, with plans for a closed-loop version including an insulin-dosing algorithm in a future FDA submission.お知らせ • Dec 20Embecta Corp., Annual General Meeting, Feb 07, 2024Embecta Corp., Annual General Meeting, Feb 07, 2024, at 08:00 US Eastern Standard Time. Location: Hilton Short Hills, 41 John F. Kennedy Parkway Short Hills New Jersey United States Agenda: To consider the election as directors of the three nominees named in the attached proxy statement for a two-year term; to consider the ratification of the selection of the independent registered public accounting firm; to consider an advisory vote to approve named executive officer compensation; and to discuss the approval of an amendment to the Embecta 2022 Employee and Director Equity-Based Compensation Plan.Reported Earnings • Nov 23Full year 2023 earnings released: EPS: US$1.23 (vs US$3.92 in FY 2022)Full year 2023 results: EPS: US$1.23 (down from US$3.92 in FY 2022). Revenue: US$1.12b (flat on FY 2022). Net income: US$70.4m (down 69% from FY 2022). Profit margin: 6.3% (down from 20% in FY 2022). Revenue is forecast to stay flat during the next 2 years compared to a 6.1% growth forecast for the Medical Equipment industry in Germany.お知らせ • Nov 22+ 2 more updatesEmbecta Corp. to Report Q4, 2023 Results on Nov 21, 2023Embecta Corp. announced that they will report Q4, 2023 results on Nov 21, 2023New Risk • Nov 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.9x net interest cover). Negative equity (-US$809m). Minor Risks Short dividend paying track record (1 year of continuous dividend payments). Share price has been volatile over the past 3 months (6.7% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (4.2% net profit margin).Valuation Update With 7 Day Price Move • Aug 22Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €15.50, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 25x in the Medical Equipment industry in Germany. Total loss to shareholders of 50% over the past year.Upcoming Dividend • Aug 17Upcoming dividend of US$0.15 per share at 3.2% yieldEligible shareholders must have bought the stock before 24 August 2023. Payment date: 13 September 2023. Payout ratio is a comfortable 72% and this is well supported by cash flows. Trailing yield: 3.2%. Lower than top quartile of German dividend payers (4.8%). Higher than average of industry peers (1.9%).Reported Earnings • Aug 09Third quarter 2023 earnings released: EPS: US$0.27 (vs US$1.08 in 3Q 2022)Third quarter 2023 results: EPS: US$0.27 (down from US$1.08 in 3Q 2022). Revenue: US$286.1m (down 1.7% from 3Q 2022). Net income: US$15.2m (down 76% from 3Q 2022). Profit margin: 5.3% (down from 21% in 3Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 6.3% growth forecast for the Medical Equipment industry in Germany.お知らせ • Aug 09+ 1 more updateEmbecta Corp. Revises Earnings Guidance for the Fiscal Year 2023Embecta Corp. revised earnings guidance for the fiscal year 2023. For the year, company expects revenue $1,107 Million to $1,113 Million against previous guidance for revenue to be in range of $1,101 Million to $1,113 Million.お知らせ • Jul 06Embecta Corp. Announces Resignation of Ajay Kumar as Chief Human Resources Officer, Effective July 16, 2023On June 29, 2023, Ajay Kumar, the Chief Human Resources Officer (CHRO) of Embecta Corp. and the Company mutually agreed to Mr. Kumar’s resignation from his role as CHRO, effective July 16, 2023.Reported Earnings • May 14Second quarter 2023 earnings released: EPS: US$0.24 (vs US$1.38 in 2Q 2022)Second quarter 2023 results: EPS: US$0.24 (down from US$1.38 in 2Q 2022). Revenue: US$277.1m (flat on 2Q 2022). Net income: US$14.0m (down 82% from 2Q 2022). Profit margin: 5.1% (down from 29% in 2Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 6.4% growth forecast for the Medical Equipment industry in Germany.お知らせ • May 13+ 1 more updateEmbecta Corp. Revises Revenue Guidance for the Fiscal Year 2023Embecta Corp. revises revenue guidance for the fiscal year 2023. The company now expects revenue of $1,101 million- $1,113 million against previous forecast of $1,084 million - $1,107 million.Recent Insider Transactions • Feb 20Independent Non-Executive Chairman recently bought €96k worth of stockOn the 15th of February, David Melcher bought around 3k shares on-market at roughly €30.85 per share. This transaction amounted to 17% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was David's only on-market trade for the last 12 months.Recent Insider Transactions • Feb 17Independent Non-Executive Chairman recently bought €94k worth of stockOn the 15th of February, David Melcher bought around 3k shares on-market at roughly €30.47 per share. This transaction amounted to 17% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was David's only on-market trade for the last 12 months.お知らせ • Feb 15+ 1 more updateEmbecta Corp. Declares Quarterly Cash Dividend, Payable on March 13, 2023Embecta Corp. have declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company’s common stock. The dividend is payable on March 13, 2023 to stockholders of record at the close of business on February 27, 2023.Reported Earnings • Feb 15First quarter 2023 earnings releasedFirst quarter 2023 results: EPS: US$0.62. Revenue: US$275.7m (down 4.7% from 1Q 2022). Net income: US$35.2m (down 64% from 1Q 2022). Profit margin: 13% (down from 34% in 1Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 6.2% growth forecast for the Medical Equipment industry in Germany.Valuation Update With 7 Day Price Move • Jan 28Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €24.40, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 27x in the Medical Equipment industry in Europe.お知らせ • Jan 25Embecta Corp. to Report Q1, 2023 Results on Feb 14, 2023Embecta Corp. announced that they will report Q1, 2023 results on Feb 14, 2023Valuation Update With 7 Day Price Move • Dec 31Investor sentiment deteriorated over the past weekAfter last week's 20% share price decline to €24.00, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 28x in the Medical Equipment industry in Europe.Reported Earnings • Dec 24Full year 2022 earnings releasedFull year 2022 results: EPS: US$3.92. Revenue: US$1.13b (down 3.0% from FY 2021). Net income: US$223.6m (down 46% from FY 2021). Profit margin: 20% (down from 36% in FY 2021). The decrease in margin was primarily driven by higher expenses. Revenue is expected to decline by 2.8% p.a. on average during the next 2 years, while revenues in the Medical Equipment industry in Germany are expected to grow by 5.5%.お知らせ • Dec 21+ 1 more updateEmbecta Corp. Provides Revenue Guidance for the Fiscal Year 2023Embecta Corp. provided revenue guidance for the fiscal year 2023. for the year, the company expects revenue in the range of $1,050 million to $1,073 million.Board Change • Nov 16High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. No experienced directors. No highly experienced directors. Independent Director Bob Hombach is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Board Change • Oct 28High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. No experienced directors. No highly experienced directors. Independent Director Bob Hombach is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Oct 01Embecta Corp., Annual General Meeting, Feb 09, 2023Embecta Corp., Annual General Meeting, Feb 09, 2023.お知らせ • Sep 19Embecta Corp.(NasdaqGS:EMBC) dropped from FTSE All-World Index (USD)Embecta Corp.(NasdaqGS:EMBC) dropped from FTSE All-World Index (USD)Reported Earnings • Aug 17Third quarter 2022 earnings releasedThird quarter 2022 results: EPS: US$1.08. Net income: US$62.4m (up US$62.4m from 3Q 2021). Over the next year, revenue is expected to shrink by 3.1% compared to a 7.6% growth forecast for the Medical Equipment industry in Germany.お知らせ • Aug 16+ 1 more updateEmbecta Corp. Revises Revenue Guidance for the Second-Half Fiscal Year 2022Embecta Corp. revised revenue guidance for the Second-Half Fiscal Year 2022. For the period, the company expects Revenues of approximately $555 million compared to $555 million previous guidance.業績と収益の成長予測DB:JX7 - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数9/30/20281,09291123N/A39/30/20271,08377123N/A49/30/20261,02153106N/A43/31/20261,043112205214N/A12/31/20251,080140206214N/A9/30/20251,08095182192N/A6/30/20251,10384132134N/A3/31/20251,080534051N/A12/31/20241,108582944N/A9/30/20241,123782036N/A6/30/20241,119701439N/A3/31/20241,13370932N/A12/31/20231,12255-30-6N/A9/30/20231,121704168N/A6/30/20231,114477096N/A3/31/20231,11994114138N/A12/31/20221,116160309334N/A9/30/20221,130224388412N/A6/30/20221,156338411440N/A3/31/20221,160380506537N/A12/31/20211,169408442474N/A9/30/20211,165415417456N/A9/30/20201,086428457499N/A9/30/20191,109432N/A505N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: JX7の収益は今後 3 年間で減少すると予測されています (年間-1.9% )。収益対市場: JX7の収益は今後 3 年間で減少すると予測されています (年間-1.9% )。高成長収益: JX7の収益は今後 3 年間で減少すると予測されています。収益対市場: JX7の収益 ( 1.7% ) German市場 ( 6.7% ) よりも低い成長が予測されています。高い収益成長: JX7の収益 ( 1.7% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: JX7の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/28 21:43終値2026/05/28 00:00収益2026/03/31年間収益2025/09/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Embecta Corp. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7 アナリスト機関Travis SteedBofA Global ResearchTravis SteedBofA Global ResearchMichael GormanBTIG4 その他のアナリストを表示
お知らせ • Nov 25+ 1 more updateEmbecta Corp. Provides Earnings Guidance for the Fiscal Year 2026Embecta Corp. provided earnings guidance for the fiscal year 2026. For the year, the company expects reported revenues of $1,071 million to $1,093 million.
お知らせ • May 22Embecta Corp. Re-Affirms Earnings Guidance for the Fiscal Year 2025Embecta Corp. re-affirmed earnings guidance for the fiscal year 2025. For the year, the company expected Reported Revenues of $1,073 million - $1,090 million.
お知らせ • Feb 06+ 1 more updateEmbecta Corp. Revises Earnings Guidance for the Fiscal Year 2025Embecta Corp. revised earnings guidance for the Fiscal Year 2025 . For the year, company expected Reported Revenues to be in range of $1,075 million to $1,092 million compared to $1,093 million to $1,110 million.
お知らせ • Nov 26+ 1 more updateEmbecta Corp. Provides Earnings Guidance for the Fiscal Year 2025Embecta Corp. provided earnings guidance for the Fiscal Year 2025 . For the year, company expected Reported Revenues to be in range of $1,093 million to $1,110 million.
お知らせ • Aug 09+ 1 more updateEmbecta Corp. Revises Earnings Guidance for the Fiscal Year 2024Embecta Corp. revised earnings guidance for the fiscal year 2024. For the fiscal year, the Company now expects revenues of $1,111 million to $1,116 million same as previous guidance of $1,111 million to $1,116 million.
お知らせ • May 10+ 1 more updateEmbecta Corp. Provides Earnings Guidance for the Fiscal Year 2024Embecta Corp. provided earnings guidance for the fiscal year 2024. For the year, the company expects revenues to be $1,111 million -$1,116 million against previous guidance of $1,094 million- $1,116 million.
Board Change • May 21Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Lead Independent Director Claire Pomeroy was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • May 06Embecta Corp. (NasdaqGS:EMBC) announces an Equity Buyback for $100 million worth of its shares.Embecta Corp. (NasdaqGS:EMBC) announces a share repurchase program. Under the program, the company will repurchase up to $100 million worth of its stock. The program is valid for 3 years.
お知らせ • Feb 12Embecta Announces Board Changes, Effective February 11, 2026Embecta announced that its board of directors elected the company’s CEO, Devdatt “Dev” Kurdikar, as chair. The Parsippany, New Jersey-based BD Diabetes spinoff also named Dr. Claire Pomeroy as lead independent director. Both appointments go into effect immediately. These changes follow the retirement of David Melcher, who previously served as non-executive chair of the board. Kurdikar,57, joined BD in 2021 to join the company’s diabetes care business, overseeing it during its separation from the medtech giant. He assumed the role of president and CEO of Embecta following the 2022 spin-off, also joining the company’s board. Changes come atop the company’s board as Embecta works through brand transition program through a phased plan to create value and shift priorities toward broader medical applications. Pomeroy,70, joined Embecta’s board of directors at its inception in 2022. In addition to serving as lead independent director, she will continue to chair the board’s Corporate Governance and Nominating Committee and serve on the Technology, Quality and Regulatory Committee. Other roles for Pomeroy include president of the Albert and Mary Lasker Foundation, a private foundation. It seeks to improve health by accelerating support for medical research through research excellence, public education and advocacy. Pomeroy also serves as a director of Haemonetics and on a number of other boards across several foundations, centers, labs, schools and more.
お知らせ • Feb 06Embecta Corp. Announces Quarterly Cash Dividend, Payable on March 17, 2026Embecta Corp. has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company’s common stock. The dividend is payable on March 17, 2026 to stockholders of record at the close of business on February 27, 2026.
お知らせ • Dec 19Embecta Corp., Annual General Meeting, Feb 11, 2026Embecta Corp., Annual General Meeting, Feb 11, 2026.
お知らせ • Nov 25+ 1 more updateEmbecta Corp. Provides Earnings Guidance for the Fiscal Year 2026Embecta Corp. provided earnings guidance for the fiscal year 2026. For the year, the company expects reported revenues of $1,071 million to $1,093 million.
お知らせ • Nov 18Embecta Corp. Announces Board ChangesEmbecta Corp. announced that on November 17, 2025, David A. Albritton, a member of the board of directors of the company, the Corporate Governance and Nominating Committee of the Board and the Technology, Quality and Regulatory Committee of the Board, notified the Company of his intention to resign due to personal reasons, effective immediately. Mr. Albritton has served as a director of the Company since April 2022. Mr. Albritton’s resignation was not the result of any disagreement with the Company or any matter relating to its operations, policies or practices. On November 17, 2025, LTG (Ret.) David F. Melcher, a member of the Board and the Non-Executive Chairman of the Board, notified the Company of his decision not to stand for re-election at the Company’s 2026 annual meeting of stockholders. LTG Melcher has served as a director of the Company since April 2022. LTG Melcher’s decision not to stand for reelection was not the result of any disagreement with the Company or any matter relating to its operations, policies or practices. In connection with the resignation of Mr. Albritton, the size of the Board was decreased from nine to eight members. The Company’s independent directors expect to appoint Devdatt (Dev) Kurdikar as the Chairman of the Board and Dr. Claire Pomeroy as the Board’s Lead Independent Director, each effective upon LTG Melcher’s departure from the Board at the Company’s 2026 annual meeting of stockholders. Dr. Pomeroy and Mr. Kurdikar have served on the Board since April 2022. Dr. Pomeroy currently serves as Chair of the Corporate Governance and Nominating Committee and as a member of the Technology, Quality and Regulatory Committee, and Mr. Kurdikar currently serves as the President and Chief Executive Officer of the Company.
お知らせ • Nov 12Embecta Corp. to Report Q4, 2025 Results on Nov 25, 2025Embecta Corp. announced that they will report Q4, 2025 results on Nov 25, 2025
お知らせ • Aug 08Embecta Corp. Declares Quarterly Cash Dividend, Payable on September 15, 2025The Board of Directors of Embecta Corp. has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company’s common stock. The dividend is payable on September 15, 2025 to stockholders of record at the close of business on August 29, 2025.
お知らせ • May 22Embecta Corp. Re-Affirms Earnings Guidance for the Fiscal Year 2025Embecta Corp. re-affirmed earnings guidance for the fiscal year 2025. For the year, the company expected Reported Revenues of $1,073 million - $1,090 million.
お知らせ • May 09+ 1 more updateEmbecta Corp. Announces Quarterly Cash Dividend, Payable on June 13, 2025The Board of Directors of Embecta Corp. has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company’s common stock. The dividend is payable on June 13, 2025 to stockholders of record at the close of business on May 28, 2025.
お知らせ • Apr 22Embecta Corp. to Report Q2, 2025 Results on May 09, 2025Embecta Corp. announced that they will report Q2, 2025 results on May 09, 2025
お知らせ • Feb 06+ 1 more updateEmbecta Corp. Revises Earnings Guidance for the Fiscal Year 2025Embecta Corp. revised earnings guidance for the Fiscal Year 2025 . For the year, company expected Reported Revenues to be in range of $1,075 million to $1,092 million compared to $1,093 million to $1,110 million.
お知らせ • Jan 24Embecta Corp. to Report Q1, 2025 Results on Feb 06, 2025Embecta Corp. announced that they will report Q1, 2025 results on Feb 06, 2025
お知らせ • Dec 20Embecta Corp., Annual General Meeting, Feb 12, 2025Embecta Corp., Annual General Meeting, Feb 12, 2025. Location: the hilton short hills, 41 john f. kennedy parkway, short hills, new jersey, United States
お知らせ • Dec 03Embecta Corp. Announces Executive ChangesEmbecta Corp. appointed Anthony Roth as Chief Accounting Officer and Corporate Controller of the Company and principal accounting officer of the Company, effective as of December 2, 2024. Prior to joining the Company, Mr. Roth, 51, served as Senior Vice President, Chief Accounting Officer for Ascential plc’s Digital Commerce business during 2023 and as Chief Accounting Officer and Corporate Controller for Summit Health, from 2020 to 2023. Prior to his time with Summit Health, he served as Senior Vice President, Finance and Corporate Controller with Phibro Animal Health Corporation. Mr. Roth, a certified public accountant, has also held various accounting and financial reporting positions across several companies, including Squarespace Inc., ConvaTec Inc. and Travelport Limited. In connection with the appointment of Mr. Roth, Jake Elguicze stepped down as the Company’s principal accounting officer, effective December 2, 2024. Mr. Elguicze will continue to serve as the Company’s Chief Financial Officer and principal financial officer.
お知らせ • Dec 01Embecta Corp. announced delayed annual 10-K filingOn 11/29/2024, Embecta Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Nov 26+ 1 more updateEmbecta Corp. Provides Earnings Guidance for the Fiscal Year 2025Embecta Corp. provided earnings guidance for the Fiscal Year 2025 . For the year, company expected Reported Revenues to be in range of $1,093 million to $1,110 million.
お知らせ • Nov 13Embecta Corp. to Report Q4, 2024 Results on Nov 26, 2024Embecta Corp. announced that they will report Q4, 2024 results on Nov 26, 2024
Valuation Update With 7 Day Price Move • Nov 08Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €14.90, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 23x in the Medical Equipment industry in Germany. Total returns to shareholders of 10% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €28.37 per share.
お知らせ • Sep 03Embecta Corp. Receives 510(k) Clearance from the U.S. Food and Drug Administration for Disposable Insulin Delivery SystemEmbecta Corp. announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its proprietary disposable insulin delivery system. Indicated for adults who require insulin to manage diabetes, including both type 1 (T1D) and type 2 (T2D), the system includes a tubeless patch pump design with a 300-unit insulin reservoir that was informed by feedback from people with T2D and their healthcare providers. The system includes a wearable, fully disposable patch pump that provides adjustable basal and bolus insulin for up to three days, depending on the needs of the user. The patch pump features a 300-unit insulin reservoir that accommodates people who have higher daily insulin needs, which is typically true of people with T2D. For such people, the on-market patch pumps may not hold enough insulin to meet their needs for three days. For example, a recent embecta-sponsored study showed that a 300-unit insulin reservoir would meet the needs of 64% of adults with T2D for three-day wear, while a 200-unit reservoir would only meet the needs of 38% of that same population. In addition to the patch pump, the system comprises a locked-down controller featuring Bluetooth wireless technology with a color touchscreen designed to create a simplified interface and user experience. embecta’s patch pump development program also includes plans for a closed-loop version including an insulin-dosing algorithm in a future FDA submission.
Valuation Update With 7 Day Price Move • Aug 30Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €13.80, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 25x in the Medical Equipment industry in Germany. Total loss to shareholders of 13% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €22.16 per share.
Upcoming Dividend • Aug 21Upcoming dividend of US$0.15 per shareEligible shareholders must have bought the stock before 27 August 2024. Payment date: 13 September 2024. Payout ratio is a comfortable 50% but the company is paying out more than the cash it is generating. Trailing yield: 4.4%. Lower than top quartile of German dividend payers (4.8%). Higher than average of industry peers (1.9%).
Declared Dividend • Aug 15Third quarter dividend of US$0.15 announcedShareholders will receive a dividend of US$0.15. Ex-date: 27th August 2024 Payment date: 13th September 2024 Dividend yield will be 4.3%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by earnings (50% earnings payout ratio) but not covered by cash flows (253% cash payout ratio). The dividend has not increased over the past 2 years but payments have been stable during that time. EPS is expected to grow by 61% over the next 2 years, which should provide support to the dividend and adequate earnings cover.
Reported Earnings • Aug 11Third quarter 2024 earnings released: EPS: US$0.25 (vs US$0.27 in 3Q 2023)Third quarter 2024 results: EPS: US$0.25 (down from US$0.27 in 3Q 2023). Revenue: US$272.5m (down 4.8% from 3Q 2023). Net income: US$14.7m (down 3.3% from 3Q 2023). Profit margin: 5.4% (up from 5.3% in 3Q 2023). Revenue is forecast to stay flat during the next 3 years compared to a 6.5% growth forecast for the Medical Equipment industry in Germany.
お知らせ • Aug 09+ 1 more updateEmbecta Corp. Revises Earnings Guidance for the Fiscal Year 2024Embecta Corp. revised earnings guidance for the fiscal year 2024. For the fiscal year, the Company now expects revenues of $1,111 million to $1,116 million same as previous guidance of $1,111 million to $1,116 million.
New Risk • Jul 24New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.7x net interest cover). Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-US$770m). Minor Risks Dividend is not well covered by cash flows (368% cash payout ratio). Large one-off items impacting financial results.
お知らせ • Jul 19Embecta Corp. to Report Q3, 2024 Results on Aug 09, 2024Embecta Corp. announced that they will report Q3, 2024 results on Aug 09, 2024
Valuation Update With 7 Day Price Move • Jul 18Investor sentiment improves as stock rises 18%After last week's 18% share price gain to €11.90, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 26x in the Medical Equipment industry in Germany. Total loss to shareholders of 29% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €5.25 per share.
Valuation Update With 7 Day Price Move • May 16Investor sentiment improves as stock rises 30%After last week's 30% share price gain to €13.30, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 27x in the Medical Equipment industry in Germany. Total loss to shareholders of 46% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €5.81 per share.
Declared Dividend • May 13Second quarter dividend of US$0.15 announcedShareholders will receive a dividend of US$0.15. Ex-date: 24th May 2024 Payment date: 14th June 2024 Dividend yield will be 4.4%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by earnings (49% earnings payout ratio) but not covered by cash flows (368% cash payout ratio). The dividend has not increased over the past 2 years but payments have been stable during that time. EPS is expected to grow by 60% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
New Risk • May 10New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 4.9% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.5x net interest cover). Negative equity (-US$770m). Earnings are forecast to decline by an average of 4.9% per year for the foreseeable future. Minor Risks Dividend is not well covered by cash flows (368% cash payout ratio). Share price has been volatile over the past 3 months (9.0% average weekly change).
お知らせ • May 10+ 1 more updateEmbecta Corp. Provides Earnings Guidance for the Fiscal Year 2024Embecta Corp. provided earnings guidance for the fiscal year 2024. For the year, the company expects revenues to be $1,111 million -$1,116 million against previous guidance of $1,094 million- $1,116 million.
Reported Earnings • May 10Second quarter 2024 earnings released: EPS: US$0.50 (vs US$0.24 in 2Q 2023)Second quarter 2024 results: EPS: US$0.50 (up from US$0.24 in 2Q 2023). Revenue: US$287.2m (up 3.6% from 2Q 2023). Net income: US$28.9m (up 106% from 2Q 2023). Profit margin: 10% (up from 5.1% in 2Q 2023). The increase in margin was primarily driven by higher revenue. Revenue is forecast to stay flat during the next 3 years compared to a 7.0% growth forecast for the Medical Equipment industry in Germany.
お知らせ • Apr 24Embecta Corp. to Report Q2, 2024 Results on May 09, 2024Embecta Corp. announced that they will report Q2, 2024 results on May 09, 2024
Valuation Update With 7 Day Price Move • Apr 16Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to €9.50, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 23x in the Medical Equipment industry in Germany. Total loss to shareholders of 61% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €5.01 per share.
Upcoming Dividend • Feb 20Upcoming dividend of US$0.15 per shareEligible shareholders must have bought the stock before 27 February 2024. Payment date: 15 March 2024. Payout ratio is a comfortable 62% but the company is not cash flow positive. Trailing yield: 4.1%. Lower than top quartile of German dividend payers (5.1%). Higher than average of industry peers (1.6%).
Valuation Update With 7 Day Price Move • Feb 16Investor sentiment deteriorates as stock falls 26%After last week's 26% share price decline to €13.30, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 24x in the Medical Equipment industry in Germany. Total loss to shareholders of 53% over the past year.
Declared Dividend • Feb 14First quarter dividend of US$0.15 announcedShareholders will receive a dividend of US$0.15. Ex-date: 27th February 2024 Payment date: 15th March 2024 Dividend yield will be 4.2%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by earnings (62% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years. EPS is expected to grow by 111% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Reported Earnings • Feb 11First quarter 2024 earnings released: EPS: US$0.35 (vs US$0.62 in 1Q 2023)First quarter 2024 results: EPS: US$0.35 (down from US$0.62 in 1Q 2023). Revenue: US$277.3m (flat on 1Q 2023). Net income: US$20.1m (down 43% from 1Q 2023). Profit margin: 7.2% (down from 13% in 1Q 2023). Revenue is forecast to stay flat during the next 3 years compared to a 6.5% growth forecast for the Medical Equipment industry in Germany.
New Risk • Feb 10New major risk - Revenue and earnings growthEarnings have declined by 40% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.1x net interest cover). Negative equity (-US$822m). Earnings have declined by 40% per year over the past 5 years. Minor Risks Short dividend paying track record (1 year of continuous dividend payments). Profit margins are more than 30% lower than last year (6.3% net profit margin).
お知らせ • Feb 09+ 1 more updateEmbecta Corp. Updates Earnings Guidance for the Fiscal Year 2024Embecta Corp. updated earnings guidance for the fiscal year 2024. For the year 2024, the company expected revenues to be $1,094 million to $1,116 million against $1,085 million to $1,105 million previous guidance.
お知らせ • Jan 25Embecta Corp. to Report Q1, 2024 Results on Feb 09, 2024Embecta Corp. announced that they will report Q1, 2024 results on Feb 09, 2024
お知らせ • Jan 09Embecta Corp. Announces Food and Drug Administration 510(K) Submission for Insulin Patch PumpEmbecta Corp. announced that it has submitted a 510(k) premarket filing to the U.S. Food and Drug Administration (FDA) for a proprietary disposable insulin delivery system. embecta continues to advance its patch pump development program, with plans for a closed-loop version including an insulin-dosing algorithm in a future FDA submission.
お知らせ • Dec 20Embecta Corp., Annual General Meeting, Feb 07, 2024Embecta Corp., Annual General Meeting, Feb 07, 2024, at 08:00 US Eastern Standard Time. Location: Hilton Short Hills, 41 John F. Kennedy Parkway Short Hills New Jersey United States Agenda: To consider the election as directors of the three nominees named in the attached proxy statement for a two-year term; to consider the ratification of the selection of the independent registered public accounting firm; to consider an advisory vote to approve named executive officer compensation; and to discuss the approval of an amendment to the Embecta 2022 Employee and Director Equity-Based Compensation Plan.
Reported Earnings • Nov 23Full year 2023 earnings released: EPS: US$1.23 (vs US$3.92 in FY 2022)Full year 2023 results: EPS: US$1.23 (down from US$3.92 in FY 2022). Revenue: US$1.12b (flat on FY 2022). Net income: US$70.4m (down 69% from FY 2022). Profit margin: 6.3% (down from 20% in FY 2022). Revenue is forecast to stay flat during the next 2 years compared to a 6.1% growth forecast for the Medical Equipment industry in Germany.
お知らせ • Nov 22+ 2 more updatesEmbecta Corp. to Report Q4, 2023 Results on Nov 21, 2023Embecta Corp. announced that they will report Q4, 2023 results on Nov 21, 2023
New Risk • Nov 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.9x net interest cover). Negative equity (-US$809m). Minor Risks Short dividend paying track record (1 year of continuous dividend payments). Share price has been volatile over the past 3 months (6.7% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (4.2% net profit margin).
Valuation Update With 7 Day Price Move • Aug 22Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €15.50, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 25x in the Medical Equipment industry in Germany. Total loss to shareholders of 50% over the past year.
Upcoming Dividend • Aug 17Upcoming dividend of US$0.15 per share at 3.2% yieldEligible shareholders must have bought the stock before 24 August 2023. Payment date: 13 September 2023. Payout ratio is a comfortable 72% and this is well supported by cash flows. Trailing yield: 3.2%. Lower than top quartile of German dividend payers (4.8%). Higher than average of industry peers (1.9%).
Reported Earnings • Aug 09Third quarter 2023 earnings released: EPS: US$0.27 (vs US$1.08 in 3Q 2022)Third quarter 2023 results: EPS: US$0.27 (down from US$1.08 in 3Q 2022). Revenue: US$286.1m (down 1.7% from 3Q 2022). Net income: US$15.2m (down 76% from 3Q 2022). Profit margin: 5.3% (down from 21% in 3Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 6.3% growth forecast for the Medical Equipment industry in Germany.
お知らせ • Aug 09+ 1 more updateEmbecta Corp. Revises Earnings Guidance for the Fiscal Year 2023Embecta Corp. revised earnings guidance for the fiscal year 2023. For the year, company expects revenue $1,107 Million to $1,113 Million against previous guidance for revenue to be in range of $1,101 Million to $1,113 Million.
お知らせ • Jul 06Embecta Corp. Announces Resignation of Ajay Kumar as Chief Human Resources Officer, Effective July 16, 2023On June 29, 2023, Ajay Kumar, the Chief Human Resources Officer (CHRO) of Embecta Corp. and the Company mutually agreed to Mr. Kumar’s resignation from his role as CHRO, effective July 16, 2023.
Reported Earnings • May 14Second quarter 2023 earnings released: EPS: US$0.24 (vs US$1.38 in 2Q 2022)Second quarter 2023 results: EPS: US$0.24 (down from US$1.38 in 2Q 2022). Revenue: US$277.1m (flat on 2Q 2022). Net income: US$14.0m (down 82% from 2Q 2022). Profit margin: 5.1% (down from 29% in 2Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 6.4% growth forecast for the Medical Equipment industry in Germany.
お知らせ • May 13+ 1 more updateEmbecta Corp. Revises Revenue Guidance for the Fiscal Year 2023Embecta Corp. revises revenue guidance for the fiscal year 2023. The company now expects revenue of $1,101 million- $1,113 million against previous forecast of $1,084 million - $1,107 million.
Recent Insider Transactions • Feb 20Independent Non-Executive Chairman recently bought €96k worth of stockOn the 15th of February, David Melcher bought around 3k shares on-market at roughly €30.85 per share. This transaction amounted to 17% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was David's only on-market trade for the last 12 months.
Recent Insider Transactions • Feb 17Independent Non-Executive Chairman recently bought €94k worth of stockOn the 15th of February, David Melcher bought around 3k shares on-market at roughly €30.47 per share. This transaction amounted to 17% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was David's only on-market trade for the last 12 months.
お知らせ • Feb 15+ 1 more updateEmbecta Corp. Declares Quarterly Cash Dividend, Payable on March 13, 2023Embecta Corp. have declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company’s common stock. The dividend is payable on March 13, 2023 to stockholders of record at the close of business on February 27, 2023.
Reported Earnings • Feb 15First quarter 2023 earnings releasedFirst quarter 2023 results: EPS: US$0.62. Revenue: US$275.7m (down 4.7% from 1Q 2022). Net income: US$35.2m (down 64% from 1Q 2022). Profit margin: 13% (down from 34% in 1Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 6.2% growth forecast for the Medical Equipment industry in Germany.
Valuation Update With 7 Day Price Move • Jan 28Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €24.40, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 27x in the Medical Equipment industry in Europe.
お知らせ • Jan 25Embecta Corp. to Report Q1, 2023 Results on Feb 14, 2023Embecta Corp. announced that they will report Q1, 2023 results on Feb 14, 2023
Valuation Update With 7 Day Price Move • Dec 31Investor sentiment deteriorated over the past weekAfter last week's 20% share price decline to €24.00, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 28x in the Medical Equipment industry in Europe.
Reported Earnings • Dec 24Full year 2022 earnings releasedFull year 2022 results: EPS: US$3.92. Revenue: US$1.13b (down 3.0% from FY 2021). Net income: US$223.6m (down 46% from FY 2021). Profit margin: 20% (down from 36% in FY 2021). The decrease in margin was primarily driven by higher expenses. Revenue is expected to decline by 2.8% p.a. on average during the next 2 years, while revenues in the Medical Equipment industry in Germany are expected to grow by 5.5%.
お知らせ • Dec 21+ 1 more updateEmbecta Corp. Provides Revenue Guidance for the Fiscal Year 2023Embecta Corp. provided revenue guidance for the fiscal year 2023. for the year, the company expects revenue in the range of $1,050 million to $1,073 million.
Board Change • Nov 16High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. No experienced directors. No highly experienced directors. Independent Director Bob Hombach is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Board Change • Oct 28High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. No experienced directors. No highly experienced directors. Independent Director Bob Hombach is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Oct 01Embecta Corp., Annual General Meeting, Feb 09, 2023Embecta Corp., Annual General Meeting, Feb 09, 2023.
お知らせ • Sep 19Embecta Corp.(NasdaqGS:EMBC) dropped from FTSE All-World Index (USD)Embecta Corp.(NasdaqGS:EMBC) dropped from FTSE All-World Index (USD)
Reported Earnings • Aug 17Third quarter 2022 earnings releasedThird quarter 2022 results: EPS: US$1.08. Net income: US$62.4m (up US$62.4m from 3Q 2021). Over the next year, revenue is expected to shrink by 3.1% compared to a 7.6% growth forecast for the Medical Equipment industry in Germany.
お知らせ • Aug 16+ 1 more updateEmbecta Corp. Revises Revenue Guidance for the Second-Half Fiscal Year 2022Embecta Corp. revised revenue guidance for the Second-Half Fiscal Year 2022. For the period, the company expects Revenues of approximately $555 million compared to $555 million previous guidance.